Among all the promising targeted drugs, brigatinib, one of the second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (ALK-TKIs), has robust therapeutic efficacy in patients with ALK-positive NSCLC compared with crizotinib (Camidge et al., 2018). The gene discussed is ALK; the disease is non-small cell lung carcinoma.